Translational & Precision Medicine (TPM) Network

Network Goals

Scientific Expertise:

The Translational & Precision Medicine (TPM) Network and associated Communities facilitate interactions among experts across multidisciplinary fields to foster translational science with a focus on individuals via patient care and society via healthcare. The interactions are through social media, email blasts, and teleconferences with focused scientific content.

Catalyst for Innovation:

The TPM Network is a catalyst for innovation by sponsoring a range of scientific programs at the Annual Meeting focused on translational and precision medicine.

Influence and Impact:

The TPM Network is the lead group engaged in translational and precision medicine and optimal pharmacotherapy in patient care.

Education and Communication:

The TPM Network offers educational opportunities via the Communities.

Organizational Effectiveness:

Leadership within TPM is expanded by a Network Steering Committee.
The TPM Network has regularly scheduled teleconferences and utilizes social media to engage members throughout the year.
The TPM Network fosters the career of its members by assisting Communities in recognizing members for individual achievements and contributions to ASCPT, sponsoring educational programming in translational and precision medicine, and providing opportunities for networking activities throughout an individual’s career.

ASCPT Members-Only Webinar Presented by the Pharmacogenomics Community (PGx)
Title: Functional annotation of variants of uncertain significance
Date and Time: 2:00 PM EST, Monday, December 10, 2018
Speakers: Dr. Kiran Musunuru
Moderator: Dr. Sonal Singh
Description: The presentation will describe an approach based on induced pluripotent stem cells (iPSCs) to functionally annotate variants of uncertain significance in cardiomyopathy-associated genes. The platform makes use of CRISPR-Cas9 and other gene-editing tools to rapidly insert or correct patients’ variants in iPSCs, followed by differentiation of the iPSCs into cardiomyocytes in a dish. Various properties of these cardiomyocytes—such as morphological and electrophysiological characteristics—can provide insight into whether the variants are benign or pathogenic. The approach has been used for annotation of patients’ variants in TNNT2 and LMNA and has been developed to the point that it can be used to inform patient management in real time. A specific example regarding a 65-year-old woman with hypertrophic cardiomyopathy and a variant of uncertain significance in TNNT2, which was successfully annotated between her first and second clinic visits and had implications for cascade genetic testing of her children and grandchildren, will be highlighted.
Registration: https://attendee.gotowebinar.com/register/5191457794941374978